Suramin as a possible treatment for Autism, ME CFS and Long Covid

PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101

TARRYTOWN, New York, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- , Inc. (Nasdaq: ), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, announced today the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (RLS). These assets were previously dedicated to the study of suramin's potential efficacy in treating acute kidney injury resulting from chronic kidney disease.

The newly acquired data from RLS will play a crucial role in bolstering PaxMedica's ongoing efforts to support the submission for the approval of PAX-101, specifically for the treatment of African Sleeping Sickness caused by the Trypanosoma brucei rhodesiense parasite.

This strategic move follows PaxMedica's recent . The integration of the valuable data from Rediscovery Life Sciences will serve as a complementary component in the planned submission for the NDA, further solidifying the company's progression toward this critical milestone. PaxMedica remains firmly on track to meet the CMC manufacturing production requirements for PAX-101 in the first half of 2024.

In a recent statement, , Chairman and CEO of PaxMedica, emphasized the significance of this acquisition, stating, "Acquiring the research assets from Rediscovery Life Sciences marks a significant leap forward in our journey to expedite the NDA submission process for PAX-101. This valuable addition of data will significantly contribute to our mission of delivering effective and life-saving treatments for Human African Sleeping Sickness."

About PaxMedica

, Inc. is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (APT) designed to address challenging neurologic disorders. Our scope encompasses a spectrum of conditions, from neurodevelopmental disorders, including Autism Spectrum Disorder (ASD), to the debilitating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), marked by both physical and cognitive burdens. At PaxMedica, we prioritize the advancement and evaluation of our flagship program, PAX-101—an intravenous suramin formulation—primarily focused on ASD treatment, while also broadening our clinical insights into its potential applications for conditions such as ME/CFS.
Click to expand...
PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101 | Morningstar
 
PaxMedica Reports First Patient Treated with PAX-101(Suramin) for Fatal African Sleeping Sickness Infection

Howard Weisman, CEO of PaxMedica, commented, "This first use of PAX-101 to treat a critically ill patient with Stage 1 HAT infection is an important milestone for the company following years of investment in the formulation and commercial scale-up of Suramin, the active pharmaceutical ingredient of PAX-101, with the company's supply chain partners. We were contacted by the government of Malawi after sustained shortages of IV Suramin in the region in the past year, and we could not ignore their pleas for help. Responding to this extraordinary request demonstrates our commitment to provide this essential medicine to some of the world's most vulnerable people."

PaxMedica, Inc. is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (APT) aimed at addressing a range of challenging neurologic disorders. Our comprehensive portfolio encompasses a spectrum of conditions, including neurodevelopmental disorders such as Autism Spectrum Disorder (ASD), as well as other critical areas within the neurology field. Additionally, we intend to provide the rest of the world with an additional, reliable source of suramin, the accepted standard of care for Stage 1, Trypanosoma Brucei Rhodesiense.

We are dedicated to the continuous development and evaluation of our pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of our efforts, particularly focused on innovative ASD treatment solutions. Our ongoing research initiatives not only prioritize the needs of ASD patients, but also extend to exploring potential therapeutic applications for related conditions.

LINK
 
You must log in or register to reply here.
Back
Top Bottom